No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall

Why did Apple change App Store rules in the EU? How will Trump’s Fed chair pick affect markets? What caused Coinbase stock to hit new high? Why is the EU extending sanctions on Russia? How did Blackstone's $2B real estate loan purchase impact CRE? Why did Tesla fire its top manufacturing exec? What risks do stablecoins pose to crypto markets?

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall

benzinga.com/news/health-care/25/06/46122410/no-accelerated-fda-approval-for-edgewises-rare-muscular-disease-drug-shares-fall

Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biotechnology company focused on developing treatments for rare muscle disorders, recently unveiled promising results from its sevasemten program for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).
Both are progressive…

This story appeared on benzinga.com, 2025-06-26 17:29:30.